Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor - Full Text View

Purpose

MEK113583 is a Phase II open-label, multi-site study to investigate the objective response rate, safety, and pharmacokinetics of GSK1120212 in subjects with BRAF mutation-positive melanoma who were previously treated with or without a BRAF inhibitor. GSK1120212 is a potent and highly selective inhibitor of MEK activation and kinase activity.

Condition	Intervention	Phase
Cancer	Drug: GSK1120212	Phase 2

Study Type:	Interventional
Study Design:	Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	An Open-Label, Multi-Center Study to Investigate the Objective Response Rate, Safety, and Pharmacokinetics of GSK1120212, a MEK Inhibitor, in BRAF Mutation-positive Melanoma Subjects Previously Treated With or Without a BRAF Inhibitor

Resource links provided by NLM:

MedlinePlus related topics: Cancer Melanoma

U.S. FDA Resources

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:

Number of participants with best confirmed response [ Time Frame: From Baseline (Day 1) until the time of the first documented evidence of a confirmed complete response or partial response (up to approximately 25 weeks) ] [ Designated as safety issue: No ]
Best confirmed response was assessed by the Investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Best response was measured either as a complete response (CR), defined as the disappearance of all target lesions and pathological lymph nodes <10 millimeters (mm), or a partial response (PR), defined as at least a 30% decrease in the sum of the diameters of target lesions. To be assigned a status of confirmed CR or PR, a confirmatory disease assessment was required no less than 28 days after the criteria for response were first met.
Number of participants with best confirmed response in the indicated subgroups of participants previously treated with standard therapy but not BRAF inhibitors [ Time Frame: From Baseline (Day 1) until the time of the first documented evidence of a confirmed CR or PR (up to approximately 25 weeks) ] [ Designated as safety issue: No ]
The number of participants with best confirmed response was analyzed for the following subgroups of participants previously treated with standard therapy but not BRAF inhibitors: (1) participants with prior (before the start of this study) brain metastases (mets); (2) participants without prior brain mets; (3) participants with BRAF mutation V600E; (4) participants with BRAF mutation V600E and no prior brain mets; and (5) participants with BRAF mutation V600K. Objective response was assessed per RECIST version 1.1. Objective response was measured either as CR, defined as the disappearance of all target lesions and pathological lymph nodes <10 mm, or PR, defined as at least a 30% decrease in the sum of the diameters of target lesions. To be assigned a status of confirmed CR or PR, a confirmatory disease assessment was required no less than 28 days after the criteria for response were first met. Brain metastasis is a cancer that has spread to the brain from another location of the body.
Number of participants with best unconfirmed response at the time of the interim analysis (Week 8) [ Time Frame: Week 8 ] [ Designated as safety issue: No ]
An interim analysis was performed using data collected approximately 12 and 13 weeks after the 30th participant was enrolled in the prior BRAF inhibitor and prior standard therapy groups, respectively. The best unconfirmed response by the investigator per RECIST version 1.1 was assessed. The study design permitted stopping the study for futility if <3 best confirmed responses were observed in the first 30 participants of each treatment arm after completing the first post-dose assessment at Week 8. Best response was measured as either a CR, defined as the disappearance of all target lesions and pathological lymph nodes <10 millimeters, or a PR, defined as at least a 30% decrease in the sum of the diameters of target lesions.

Secondary Outcome Measures:

Mean plasma concentrations [ Time Frame: Day 15, pre-dose, 0.5-2 hours (hrs) post-dose, 2-4 hrs post-dose, and 4-8 hrs post-dose; Week 4, pre-dose; Week 8, pre-dose; Week 12, pre-dose ] [ Designated as safety issue: No ]
Human plasma samples were analyzed for trametinib using a validated analytical method.
Number of participants with any Adverse Event (AE) [ Time Frame: From the date of the first dose of study medication until 28 days after the last dose (up to 477 days) ] [ Designated as safety issue: No ]
An AE is defined as any untoward medical occurrence in a subject or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered to be related to the medicinal product. AE and serious AE (SAE) data were collected from the start of the investigational product and continued until the End of Treatment Visit. Refer to the general Adverse AE/SAE module for a complete list of AEs and SAEs.
Duration of Tumor Response [ Time Frame: From the time of the first documented evidence of a confirmed CR or PR until disease progression or death due to any cause (up to approximately 40 weeks) ] [ Designated as safety issue: No ]
Duration of tumor response is defined as the time from the first documented evidence of a CR or PR to disease progression (at least a 20 percent increase in the sum of diameters of target lesions, taking as reference the smallest sum on study; unequivocal progression of non-target lesions, or the appearance of a new lesion) or death due to any cause. No participants who were previously treated with BRAF inhibitors had a CR, defined as the disappearance of all target lesions and pathological lymph nodes <10 millimeters, or a PR, defined as at least a 30% decrease in the sum of the diameters of target lesions; thus, no duration of response data can be presented.
Progression-free survival (PFS) [ Time Frame: Baseline (Day 1) until the time of disease progression or death due to any cause (up to approximately 57 weeks) ] [ Designated as safety issue: No ]
PFS is defined as the interval between the treatment start date and the earliest date of disease progression (at least a 20 percent increase in the sum of diameters of target lesions, taking as reference the smallest sum on study; unequivocal progression of non-target lesions, or the appearance of a new lesion) or death due to any cause, whichever occurred first. Participants who had not progressed or died were censored at the date of the last adequate tumor assessment at the time of the cut-off.
PFS in the indicated subgroups of participants previously treated with standard therapy but not BRAF inhibitors [ Time Frame: Baseline (Day 1) until the time of disease progression or death due to any cause (up to approximately 57 weeks) ] [ Designated as safety issue: No ]
PFS was analyzed for the following subgroups of participants previously treated with standard therapy but not BRAF inhibitors: (1) participants with prior (before the start of this study) brain metastases (mets); (2) participants without prior brain mets; (3) participants with BRAF mutation V600E; (4) participants with BRAF mutation V600E and no prior brain mets; and (5) participants with BRAF mutation V600K. Per RECIST version 1.1, PFS is defined as the interval between the treatment start date and the earliest date of disease progression (at least a 20 percent increase in the sum of diameters of target lesions, taking as reference the smallest sum on study; unequivocal progression of non-target lesions, or the appearance of a new lesion) or death due to any cause, whichever occurred earliest. Brain metastasis is a cancer that has spread to the brain from another location of the body.
Overall Survival [ Time Frame: Baseline (Day 1) until death due to any cause (up to 64.1 weeks) ] [ Designated as safety issue: No ]
Overall survival is defined as the time from the treatment start date until death due to any cause. Overall survival data were not mature at the time of clinical cut-off (July 25, 2011); thus, overall survival data are not presented for those participants previously treated with standard therapy but not BRAF inhibitors. Participants who had not died were censored at the date of the last adequate tumor assessment at the time of the cut-off.
Number of participants previously treated with standard therapy but not BRAF inhibitors who survived until 6 months and 12 months from Baseline [ Time Frame: Month 6 and Month 12 ] [ Designated as safety issue: No ]
Overall survival (defined as the time from the treatment start date until death due to any cause) data were not mature at the time of clinical cut-off (July 25, 2011); thus, overall survival data are not presented for those participants previously treated with standard therapy but not BRAF inhibitors. For these participants, data are presented as the number of participants who were alive 6 months and 12 months after Baseline. Participants who had not died were censored at the date of the last adequate tumor assessment at the time of the cut-off.
Number of participants with tumor progression [ Time Frame: Baseline (Day 1) until tumor progression (up to approximately 57 weeks) ] [ Designated as safety issue: No ]
Tumor progression was assessed as disease progression (DP), defined as at least a 20 percent increase in the sum of diameters of target lesions (representative of all involved organs), taking as reference the smallest sum on study; unequivocal progression of non-target lesions; or the appearance of a new lesion. Because melanoma often progresses to the brain/central nervous system (CNS) and this study enrolled approximately 20% participants with prior brain metastases, tumor progression in the brain/CNS was summarized. Paticipants could have been included in more than one category.

Enrollment:	97
Study Start Date:	December 2009
Study Completion Date:	January 2013
Primary Completion Date:	July 2011 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Cohort A Subjects who have had previous treatment with a BRAF inhibitor.	Drug: GSK1120212 Daily oral dosing
Experimental: Cohort B Subjects who have had previous chemotherapy or immunotherapy without a BRAF inhibitor.	Drug: GSK1120212 Daily oral dosing

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Metastatic cutaneous melanoma that was previously treated with: (Cohort A) a BRAF inhibitor either with or without other prior therapy. (Cohort B) at least 1 prior chemotherapy or immunotherapy, without treatment with a BRAF inhibitor.
Documented positive BRAF mutation (V600E, V600K, or V600D).
Subjects must provide archived tumor tissue or undergo fresh tumor biopsy prior to enrollment.
The subject must have a radiographically measurable tumor.
The subject is able to carry out daily life activities without significant difficulty (ECOG performance status score of 0 or 1).
Able to swallow and retain oral medication.
Sexually active subjects must use acceptable methods of contraception during the course of the study.
Adequate organ system function and blood cell counts.

Exclusion Criteria:

The subject has had major surgery or received certain types of cancer therapy within 21 days before starting the study.
Previous treatment with a MEK inhibitor.
Current use of a prohibited medication listed in the protocol.
Uncontrolled glaucoma.
Brain metastasis, unless previously treated with surgery or stereotactic radiosurgery, and the disease has been stable for at least 2 months prior to enrollment.
Current severe or uncontrolled systemic disease.
History of clinically significant heart, lung, or eye/vision problems.
Significant unresolved side effects from previous anti-cancer therapy.
The subject is pregnant or breastfeeding.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT01037127

Locations

United States, Colorado
GSK Investigational Site
Aurora, Colorado, United States, 80045
United States, New York
GSK Investigational Site
New York, New York, United States, 10016
United States, Tennessee
GSK Investigational Site
Nashville, Tennessee, United States, 37203
GSK Investigational Site
Nashville, Tennessee, United States, 37232-6307
United States, Texas
GSK Investigational Site
Houston, Texas, United States, 77030-4009

Sponsors and Collaborators

GlaxoSmithKline

Investigators

Study Director:

GSK Clinical Trials

GlaxoSmithKline

More Information

Publications:

Kim KB, Kefford R, Pavlick AC, Infante JR, Ribas A, Sosman JA, Fecher LA, Millward M, McArthur GA, Hwu P, Gonzalez R, Ott PA, Long GV, Gardner OS, Ouellet D, Xu Y, DeMarini DJ, Le NT, Patel K, Lewis KD. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol. 2013 Feb 1;31(4):482-9. doi: 10.1200/JCO.2012.43.5966. Epub 2012 Dec 17.

Responsible Party:	GlaxoSmithKline
ClinicalTrials.gov Identifier:	NCT01037127 History of Changes
Other Study ID Numbers:	113583
Study First Received:	November 25, 2009
Last Updated:	March 21, 2013
Health Authority:	United States: Food and Drug Administration Australia: Therapeutic Goods Administration

Keywords provided by GlaxoSmithKline:

GSK1120212
BRAF Inhibitor
melanoma
MEK Inhibitor

Additional relevant MeSH terms:

Melanoma
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas

ClinicalTrials.gov processed this record on June 13, 2013